HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. We have established a service system formulated as "1+2+3+4=1" and can supply original factory goods of well-known brands for P29, the core intermediate of semaglutide.
As an R&D-oriented foreign trade service provider, HiSiaddi has conducted multiple rounds of on-site inspections of P29 manufacturers relying on technological transformation cooperation with factories, possessing objective and in-depth insights into different brands. We regularly analyze various P29 manufacturers for clients to help them select matched products. Below is the brand recommendation case.
For further brand and model comparative analysis, please contact HiSiaddi customer service.
The client is MediNova GmbH, a high-end pharmaceutical enterprise headquartered in Munich, Germany, specializing in R&D and production of GLP-1 innovative drugs for metabolic diseases, with products covering high-end pharmaceutical markets across the EU and North America. The company fully complies with FDA, EMA, ICH Q7 and GMP standards, with an annual P29 (core semaglutide intermediate) procurement volume of 200 kg for commercial API production, classifying it as a typical high-end overseas client.
This is the client’s first procurement of P29 from China, with zero understanding of domestic mainstream brands, technical routes, quality tiers and model differences. After contacting 5 manufacturers, each only promoted its own products without objective cross-brand comparison or disclosure of product weaknesses, leaving the client unable to conduct horizontal benchmarking. The client feared incorrect brand selection would trigger production line, compliance and delivery risks, and entrusted HiSiaddi to conduct neutral evaluation of 3–5 major brands within 7 days and recommend matched high-end brands and models.
Through factory on-site inspections, blind sample testing, technical parameter benchmarking, client word-of-mouth verification and compliance document audits, HiSiaddi screened 5 mainstream manufacturers with GMP qualifications, hundred-kilogram production capacity and FDA/EMA compliance potential, fully sorting out their technical routes, core models, quality indicators, strengths and weaknesses:
Core models: P29-DMF99 (High-Purity Grade), P29-GMP98 (Industrial Grade) Technical route: Recombinant E. coli fermentation + three-step chromatography purification, 3,000 L fermentation scale, annual capacity 300 kg Quality indicators: Purity 99.2%–99.6%, single impurity ≤0.08%, endotoxin <0.08 EU/mg, animal-origin-free, bacteriophage-free Compliance strengths: FDA DMF filing (No. 039617), complete GMP documents, EMA audit support Advantages: Highest purity, lowest endotoxin, strong batch consistency, complete compliance documents, suitable for high-end API and new drug filings Weaknesses: Slightly higher price (10%–15% premium), longer lead time (35 days) for small batches (<50 kg)
Core models: JE3200 (High-Purity Lyophilized), JE3203 (Sterile Grade), JE3206 (Custom Grade) Technical route: High-density fermentation + exclusive packing chromatography, 1,500 L fermentation scale, annual capacity 250 kg Quality indicators: Purity 98.8%–99.3%, single impurity ≤0.1%, endotoxin <0.1 EU/mg, sterile lyophilized Compliance strengths: ISO 13485 + GMP certification, English COA and impurity research reports available Advantages: High cost performance, mature sterile processes, fast delivery (25–30 days), flexible customization, suitable for commercial production Weaknesses: No FDA DMF filing, cannot directly support US new drug applications
Core models: 20381ES01 (100 mg), 20381ES08 (1 kg), 20381ES25 (25 kg) Technical route: Enzymatic cleavage + chromatography purification, 500 L fermentation scale, annual capacity 150 kg Quality indicators: Purity 98.0%–98.5%, single impurity ≤0.2%, endotoxin <0.2 EU/mg, R&D / industrial grade Compliance strengths: ISO 9001 certification, basic GMP documents Advantages: Lowest price, flexible small-batch supply, fast delivery (20 days), suitable for R&D and pilot scale-up Weaknesses: Low purity, high endotoxin, average batch consistency, unsuitable for high-end API production
Core model: S774121 (50 mg–10 g) Technical route: Outsourced peptide chain repackaging, no independent fermentation capacity Quality indicators: Purity 97.0%–98.0%, single impurity ≤0.3%, endotoxin <0.5 EU/mg Compliance strengths: Only reagent-level certification, no GMP production qualification Advantages: Complete small packaging specifications, spot inventory, suitable for laboratory small-scale trials Weaknesses: No mass production capacity, unstable quality, no compliance documents, unsuitable for commercial manufacturing
Core model: P29-GMP97 (Industrial Lyophilized Powder) Technical route: Fermentation + simplified purification, 1,000 L fermentation scale, annual capacity 200 kg Quality indicators: Purity 97.5%–98.2%, single impurity ≤0.25%, endotoxin <0.3 EU/mg Compliance strengths: Basic GMP certification, no international compliance documents Advantages: Low price, large production capacity, suitable for low-cost mass production Weaknesses: Excessive impurities, elevated endotoxin, severe batch fluctuations, unable to pass FDA/EMA audits
Combining the client’s mid-to-high-end positioning, EMA compliance requirements, 200 kg annual demand and commercial API production needs, HiSiaddi established a four-dimensional scoring system (Quality 40%, Compliance 30%, Delivery 20%, Cost 10%) to quantitatively score the 5 brands.
· Eliminate mid/low-tier brands: Yeasen, Aladdin and Jibaikang fail quality and compliance standards and cannot satisfy EMA impurity limits and API production requirements.
· Shortlist 2 mid-to-high-end brands: Paijin Biotechnology (Primary Choice), Vazyme Biotech (Alternative), fully matching client requirements in quality, compliance and delivery.
· Recommend 3 core models: Paijin P29-DMF99, Vazyme JE3203, Vazyme JE3200, covering full scenarios from high-purity compliance to sterile mass production and cost-effective commercial supply.
Recommendation rationale: The only domestic P29 manufacturer with FDA DMF filing, offering 99.5% purity and endotoxin <0.08 EU/mg fully meeting top EMA/FDA standards. Strong batch consistency supports the client’s European API manufacturing and new drug filings directly, with 3,000 L production capacity covering the 200 kg annual demand. Applicable scenarios: Commercial API manufacturing, EMA/FDA audits, new drug applications.
Recommendation rationale: Cost-performance leader in mid-to-high-end segments with 99.0% purity and endotoxin <0.1 EU/mg and mature sterile lyophilization workflows. Delivery lead time of 25–30 days (faster than Paijin) and 10% lower pricing. Full English COA and impurity research reports satisfy compliance requirements for European commercial production. Applicable scenarios: JE3203 → sterile API manufacturing; JE3200 → conventional API production / backup capacity.
1. Yeasen Biotechnology: Purity <98.5% and elevated endotoxin failing EMA impurity limits.
2. Aladdin Biochemical: No GMP production capacity and unstable quality, only suitable for laboratory small trials.
3. Jibaikang Biotechnology: Excessive batch fluctuations and impurities unable to guarantee API batch consistency.
HiSiaddi coordinated supply of 3 batches each from Paijin and Vazyme for blind testing of purity, endotoxin, reaction activity and stability by the client:
· Paijin P29-DMF99: 99.5% purity, 0.07 EU/mg endotoxin, 92% reaction conversion rate (optimal performance)
· Vazyme JE3203: 99.1% purity, 0.09 EU/mg endotoxin, 90% reaction conversion rate (fully compliant)
· Vazyme JE3200: 99.0% purity, 0.08 EU/mg endotoxin, 89% reaction conversion rate (fully compliant)
1. First batch (50 kg): Vazyme JE3203 (30 kg) + JE3200 (20 kg) for fast delivery and production line compatibility verification.
2. Subsequent batches (150 kg): Paijin P29-DMF99 (100 kg) + Vazyme JE3203 (50 kg) balancing compliance, production capacity and cost control.
After procurement, stable production line reaction efficiency, fully compliant API impurities and consistent batch performance were achieved, enabling smooth passage of EMA audits. Overall costs decreased by 32% vs. European suppliers with delivery lead times shortened by 20 days.
Client feedback: "HiSiaddi is a truly neutral and professional selection partner breaking the industry’s 'self-promotion only' norm. It accurately matched our high-end demands, helped us avoid selection pitfalls and established a stable, compliant and cost-effective Chinese supply chain."
The client signed a 3-year exclusive procurement agreement with HiSiaddi, raising annual procurement volume to 250 kg. HiSiaddi was also appointed the exclusive technical and compliance consultant responsible for brand selection, quality audits and compliance coordination for P29 and other GLP-1 intermediates in the future.
Core pain points for overseas high-end pharmaceutical enterprises sourcing high-end polypeptide intermediates such as P29 include asymmetric brand information, manufacturers’ biased self-promotion and lack of neutral comparative evaluation. Blind brand selection may lead to substandard quality, compliance risks, production line shutdowns and delivery delays with severe consequences.
With a neutral evaluation stance, full-dimensional brand research, quantitative scoring systems and screening logic aligned with high-end client demands, HiSiaddi successfully resolved the client’s brand selection challenges:
1. Neutral and impartial: Independent evaluation based on client requirements without affiliation to any manufacturer, disclosing all weaknesses and avoiding exaggerated advantages.
2. Precise matching: Shortlisted 2 mid-to-high-end brands and 3 core models balancing quality, compliance, delivery and cost.
3. Risk mitigation: Excluded low-quality and non-compliant manufacturers to eliminate production and regulatory risks for the client.
4. Value enhancement: Delivered 32% cost reduction, 20% faster delivery and stabilized supply chains, securing long-term client trust.
This service not only supported the client in procuring matched qualified products but also set a benchmark for HiSiaddi, a Chinese enterprise, delivering neutral, professional and objective brand selection services to overseas high-end pharmaceutical manufacturers, facilitating high-end domestic pharmaceutical intermediates to accurately access the global high-end pharmaceutical market.
For further brand and model comparative analysis, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
